Botswana Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Botswana Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Botswana Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Multinational drugmaker presence in Botswana will be limited to imports as the small market size and lack of investment incentives deter any large-scale investment plans. Although generic drugs will retain their dominance in terms of market share, as the burden of non-communicable diseases increases this will create more lucrative opportunities for foreign drugmakers. The government will remain committed to reducing the longstanding HIV/AIDS burden in the country. As such, a combination of funding from the public sector and international donors will make significant progression towards achieving the UNAIDS 90-90-90 targets.

Headline Expenditure Projections

  • Pharmaceuticals: BWP1.96bn (USD190mn) in 2015 to BWP2.15bn (USD180mn) in 2016; +9.2% in local currency terms and -5.9% in US dollar terms. Forecast unchanged from Q 3 1 6 .

  • Healthcare: BWP8.34bn (USD820mn) in 2015 to BWP9.08n (USD770mn) in 2016; +8.9% in local currency terms and -6.2% in US dollar terms. Forecast unchanged from Q 3 16 .

Headline Pharmaceuticals & Healthcare Forecasts (Botswana 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.200 0.190 0.180 0.190 0.190 0.200 0.210
Pharmaceutical sales, % of GDP 1.26 1.35 1.37 1.38 1.37 1.37 1.36
Pharmaceutical sales, % of health expenditure 23.4 23.6 23.6 23.7 23.9 24.0 24.1
Health spending, USDbn 0.860 0.820 0.770 0.780 0.810 0.830 0.870

Risk/Reward Index

In our Q416 Pharmaceutical Risk/Reward Index (RRI), Botswana's score of 34.2 out of 100 marks a decrease from last quarter's score of 40.2, whilst remaining below the regional average of 40.4. This relates to the country's overall small pharmaceutical market size and lengthy approval and procurement times. Botswana will see a gradual recovery in real GDP growth over the next five years, supported by private consumption and fixed investment. However, subdued demand and prices for diamonds -Botswana's key commodity export - will continue to weigh on economic growth, which in turn will negatively impact on short-term pharmaceutical market growth. In Africa alone, Botswana is ranked tenth, highlighting the country's potential as a pharmaceutical market. The government's continued commitment to improving healthcare provision is a stand out factor here.

Latest Updates

  • In June 2016, ViiV Healthcare confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new HIV/AIDs treatment programme, through the supply of Tivicay (dolutegravir).

  • In June 2016, a progress report by the government revealed that the Botswana government has remained committed to its new community-driven roots-up HIV prevention approach.

  • In June 2016, Botswana's Minister of Health declared the need for much greater investment towards tackling the non-communicable disease burden in the country.

BMI Political View

Botswana remains the least corrupt nation in Sub-Saharan Africa following sound legal institutions and anti-corruption initiatives. The southern African nation held its rank as the least corrupt country in the region for the 20th consecutive year as rated by Transparency International. Botswana has sound institutions and a solid legal framework which include the Directorate on Corruption and Economic Crime and the Financial Intelligence Agency. The nation has additional initiatives such as a designated High Court judge to address cases of corruption, an anti-corruption unit and anti-corruption curricula in schools.

BMI Economic View

The ongoing drought and its affect on water supply and power generation will weigh on Botswana's economy in 2016. In particular, these will have an impact on the country's more positive drivers; namely the government's efforts to attract fixed investment into infrastructure, an Economic Stimulus Package in order to boost economic growth, as well as efforts to diversify the economy. As a result, we forecast real GDP growth of 3.7% for 2016 and 4.1% for 2017.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Botswana 2014-2020)
7
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Botswana 2012-2020)
11
Healthcare Market Forecast
12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Botswana 2012-2020)
14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Botswana 2012-2020)
14
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Botswana 2012-2020)
15
Botswana - Pharmaceutical Trade Forecast - Q3 2016
16
Table: Pharmaceutical Trade Data And Forecasts (Botswana 2014-2020)
18
Table: Pharmaceutical Trade Data And Forecasts local currency (Botswana 2014-2020)
18
Industry Risk/Reward Index
19
Middle East and Africa Risk/Reward Index - Q3 2016
19
Botswana Risk/Reward Index
27
Rewards
27
Risks
28
Regulatory Review
29
Intellectual Property Issues
29
Pricing & Reimbursement Regime
32
Market Overview
33
Healthcare Sector
34
Research & Development
36
Clinical Trials
37
Epidemiology
37
Competitive Landscape
40
Table: Multinational Market Activity
40
Generic Drugmakers
40
Pharmaceutical Distribution
41
Pharmaceutical Retail Sector
41
Company Profile
42
Gemi Pharmacure
42
Demographic Forecast
44
Botswana - Demographic Forecast
44
Table: Population Headline Indicators (Botswana 1990-2025)
45
Table: Key Population Ratios (Botswana 1990-2025)
45
Table: Urban/Rural Population & Life Expectancy (Botswana 1990-2025)
46
Table: Population By Age Group (Botswana 1990-2025)
46
Table: Population By Age Group % (Botswana 1990-2025)
47
Glossary
49
Methodology
51
Pharmaceutical Expenditure Forecast Model
51
Healthcare Expenditure Forecast Model
51
Notes On Methodology
52
Risk/Reward Index Methodology
53
Index Overview
54
Table: Pharmaceutical Risk/Reward Index Indicators
54
Indicator Weightings
55

The Botswana Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Botswana Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Botswana pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Botswana, to test other views - a key input for successful budgeting and strategic business planning in the Botswanan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Botswanan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Botswana.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.